2023 Esmo Congress News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from 2023 esmo congress. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In 2023 Esmo Congress Today - Breaking & Trending Today

Long-Term CheckMate 238 Data Support Adjuvant Nivolumab Vs Ipilimumab in Resected Melanoma

Adjuvant nivolumab significantly improved relapse-free survival vs ipilimumab in resected stage III/IV melanoma, according to 7-year minimum follow-up. ....

United States , Paoloa Ascierto , Istituto Nazionale Tumori , Fondazione Pascale , American Joint Committee On Cancer , American Joint Committee , Phase 3 Checkmate 238 Study , 2023 Esmo Congress , Resected Melanoma , Resected Stage Iii Or Iv Melanoma , Relapse Free Survival , 7 Year Follow Up From Checkmate 238 ,

Taletrectinib Continues to Demonstrate High Clinical Activity in Advanced ROS1+ NSCLC

Clinicians discuss data on the ROS1 TKI taletrectinib in patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer. ....

New York , United States , J Thor Onc , Christine Bestvina , Stephenv Liu , Alexander Drilon , Jason Porter , China National Medical Products Administration , Cancer Center , University Of Chicago Medicine Comprehensive Cancer Center , Georgetown University , National Medical Products Administration Of China , Research Institute , Lung Cancer Disease Research Group , Georgetown Lombardi Comprehensive Cancer Center , West Cancer Center , National Medical Products Administration , Thoracic Oncology , Developmental Therapeutics , Georgetown Lombardi Comprehensive Cancer , Early Drug Development Service , Memorial Sloan Kettering Cancer Center , Uchicago Medicine Comprehensive Cancer Center , Heart Therapeutics , Anheart Therapeutics , Ros1 Tki ,

What Fellows Need to Know: Key Takeaways From ESMO 2023

The 2023 ESMO Congress took place October 20 to 24 in Madrid, Spain, with global perspectives on groundbreaking data. We break down some of the key highlights from the annual meeting that oncology fellows should absorb, and apply to practice, as soon as possible. ....

United States , Dana Farber Cancer Institute , Region Flamande , Amivantamab Lazertinib , Thomasb Powles , Jacob Sands , International Patient Center , Harvard Medical School , Leuven Cancer Institute , Gynecologic Oncology At Catholic University Of Leuven , Department Of Obstetrics , European Society For Medical Oncology , Medical Oncology , Gynecologic Oncology , Catholic University , Breast Cancer , Lung Cancer , 2023 Esmo Congress , Genitourinary Cancers , Gastrointestinal Cancers ,

FDA Restricts Approval for Pembrolizumab Plus Trastuzumab and Chemo to Advanced PD-L1+ Gastric/GEJ Cancer

The FDA has updated the current indication for pembrolizumab plus trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for the frontline treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma to those whose tumors express PD-L1 with a CPS of 1 or more. ....

Approval For Pembrolizumab Plus Trastuzumab And Chemotherapy , Advanced Pd L1 Gastric Gej Cancer , Phase 3 Keynote 811 Trial , 2023 Esmo Congress , Lancet Oncology , Agilent Pd L1 Immunohistochemistry 22c3 Pharmdx , Pd L1 Witha Combined Positive Score Of 1 Or More , Frontline Treatment ,

Neoadjuvant Inetetamab Combo Shows Efficacy, Tolerability in Locally Advanced HER2+ Breast Cancer

The combination of inetetamab, pertuzumab, paclitaxel, and carboplatin administered elicited responses with an acceptable safety profile when administered as neoadjuvant treatment in patients with locally advanced HER2-positive breast cancer. ....

Yue Chai , Union Medical College , Chinese Academy Of Medical Sciences , National Cancer Center , Oncology Department , Medical Oncology Department , Chinese Academy , Medical Sciences , Peking Union Medical College , Cancer Hospital , Breast Cancer , Neoadjuvant Her2 , Her2 Positive Breast Cancer , 2023 Esmo Congress ,